An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

OutgoingBristolCEOGiovanniCaforioEmiliePickeringforSTATIt’schangingoftheguardtimeatpharmaceuticalgia CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy




knowledge

author：leisure time    Page View：71
Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

advertisement

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In
Previous article： Medtronic CEO on promising devices for diabetes, hypertension
Next article： How to save PrEP access — and even expand it